

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM350373

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
MIDCAP FINANCIAL TRUST		07/29/2015	LIMITED LIABILITY COMPANY:
RECEIVING PARTY DATA			
Name:	IMMUNE PHARMACEUTICALS, INC.		
Street Address:	430 EAST 29TH STREET		
Internal Address:	SUITE 940		
City:	NEW YORK		
State/Country:	NEW YORK		
Postal Code:	10016		
Entity Type:	CORPORATION: DELAWARE		
Name:	MAXIM PHARMACEUTICALS, INC.		
Street Address:	8899 UNIVERSITY CENTER LANE		
Internal Address:	SUITE 400		
City:	SAN DIEGO		
State/Country:	CALIFORNIA		
Postal Code:	92122		
Entity Type:	CORPORATION: DELAWARE		
Name:	CYTOVIA, INC.		
Street Address:	6650 NANCY RIDGE DRIVE		
City:	SAN DIEGO		
State/Country:	CALIFORNIA		
Postal Code:	92121		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Registration Number:	2967403	CEPLENE	
Serial Number:	85021009	CEPLENE	
Registration Number:	3252103	VONTIV	
Serial Number:	85009435	CROLIBULIN	
Registration Number:	3265139	EPICEPT	
TRADEMARK			

Property Type	Number	Word Mark
Registration Number:	1906291	LIDOPAIN
Registration Number:	3366649	LIDOPAIN

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: lagould@mintz.com

Correspondent Name: MINTZ LEVIN

Address Line 1: One Financial Center

Address Line 2: Stephanie Leopold

Address Line 4: Boston, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER:	46981-001
NAME OF SUBMITTER:	Leslie Gould
SIGNATURE:	/lesliegould/
DATE SIGNED:	08/05/2015

Total Attachments: 43

source=MidCapImmuneRelease1#page1.tif
source=MidCapImmuneRelease1#page2.tif
source=MidCapImmuneRelease1#page3.tif
source=MidCapImmuneRelease1#page4.tif
source=MidCapImmuneRelease1#page5.tif
source=MidCapImmuneRelease1#page6.tif
source=MidCapImmuneRelease1#page7.tif
source=MidCapImmuneRelease1#page8.tif
source=MidCapImmuneRelease1#page9.tif
source=MidCapImmuneRelease1#page10.tif
source=MidCapImmuneRelease1#page11.tif
source=MidCapImmuneRelease1#page12.tif
source=MidCapImmuneRelease1#page13.tif
source=MidCapImmuneRelease1#page14.tif
source=MidCapImmuneRelease1#page15.tif
source=MidCapImmuneRelease1#page16.tif
source=MidCapImmuneRelease1#page17.tif
source=MidCapImmuneRelease1#page18.tif
source=MidCapImmuneRelease1#page19.tif
source=MidCapImmuneRelease1#page20.tif
source=MidCapImmuneRelease1#page21.tif
source=MidCapImmuneRelease1#page22.tif
source=MidCapImmuneRelease1#page23.tif
source=MidCapImmuneRelease1#page24.tif
source=MidCapImmuneRelease1#page25.tif
source=MidCapImmuneRelease1#page26.tif
source=MidCapImmuneRelease1#page27.tif

source=MidCapImmuneRelease1#page28.tif
source=MidCapImmuneRelease1#page29.tif
source=MidCapImmuneRelease1#page30.tif
source=MidCapImmuneRelease1#page31.tif
source=MidCapImmuneRelease1#page32.tif
source=MidCapImmuneRelease1#page33.tif
source=MidCapImmuneRelease1#page34.tif
source=MidCapImmuneRelease1#page35.tif
source=MidCapImmuneRelease1#page36.tif
source=MidCapImmuneRelease1#page37.tif
source=MidCapImmuneRelease1#page38.tif
source=MidCapImmuneRelease1#page39.tif
source=MidCapImmuneRelease1#page40.tif
source=MidCapImmuneRelease1#page41.tif
source=MidCapImmuneRelease1#page42.tif
source=MidCapImmuneRelease1#page43.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this "Release") is made as of July 29, 2015 ("Effective Date") by MIDCAP FINANCIAL TRUST, in its capacity as Administrative Agent ("Grantee"), in favor of IMMUNE PHARMACEUTICALS, INC. (f/k/a EpiCept Corporation), MAXIM PHARMACEUTICALS, INC. and CYTOVIA, INC., (each a "Grantor" and, collectively, the "Grantors").

WHEREAS, pursuant to the terms and conditions of that certain Intellectual Property Security Agreement, dated as of May 27, 2011 (the "May 2011 Agreement"), Grantors assigned, transferred and conveyed to Grantee, and granted to Grantee, a security interest in all of Grantors' right, title and interest in and to the Intellectual Property Collateral (as defined in the May 2011 Agreement, the "Intellectual Property Collateral");

WHEREAS, the May 2011 Security Agreement was recorded with the United States Patent and Trademark Office on May 31, 2011 at Reel 026360, Frame 0023 and at Reel 004551, Frame 0029. A corrective filing was recorded with the United States Patent and Trademark Office on October 27, 2011 at Reel 4649, Frame 0833.

WHEREAS, Grantee has consented to the release of the lien on all of the Intellectual Property Collateral, including but not limited to the patents and trademarks listed on Schedule 1 hereto (collectively, the "Released IP Collateral");

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantee hereby covenants and agrees as follows:

1. Grantee's mortgage, pledge, and hypothecation and lien on and security interest in the Released IP Collateral is hereby terminated and released.

2. To the extent Grantee retains any such interest, Grantee hereby assigns, transfers and conveys to Grantors, all of Grantee's right, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest and collateral assignment in the Released IP Collateral. Such assignment, transfer and conveyance by Grantee is made without any representation or warranty (express or implied) by Grantee.

3. Grantee hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required in order to more fully and effectively carry out the purposes of this Release, all at the expense of Grantors. Grantee authorizes Grantors (or their agents) to file such documentation as is necessary to effect the releases of the Intellectual Property Collateral granted hereunder.

4. This Release may be executed in counterparts, each of which will be deemed an original, but all of which together constitute one and the same original. Delivery of an executed counterpart of a signature page to this Release by facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart of this Release.


[the remainder of this page intentionally left blank]

IN WITNESS WHEREOF, Grantee has caused this Release to be executed by its duly authorized representative as of the Effective Date.

MIDCAP FINANCIAL TRUST

By: Apollo Capital Management, L.P.,
its investment manager

By: Apollo Capital Management GP, LLC,
its general partner

By:  (SEAL)
Name: Maurice Amsellem
Title: Authorized Signatory

Schedule 1

[See attached]

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

[See Attached]

EpiCept Patent Portfolio (May 2011)

<u>SKGF Ref.</u>	<u>Title</u>	<u>Country</u>	<u>Patent No./Appl. No.</u>	<u>Issue Date/File Date</u>	<u>Status</u>
1735.0010001	Dipeptide Caspase Inhibitors and the Use Thereof	USA	6,153,591 09/270,735	11/28/2000 3/16/1999	Granted.
1735.0030001	Novel Fluorescence Dyes and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases, Peptidases, Proteases, and Other Enzymes and the Use Thereof	USA	6,248,904 09/357,952	6/19/2001 7/21/1999	Granted.
1735.0030003	Novel Fluorescence Dyes and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases, Peptidases, Proteases, and Other Enzymes and the Use Thereof	USA	6,984,718 10/138,375	1/10/2006 5/6/2002	Granted.
1735.0280002	Dipeptide Apoptosis Inhibitors and the Use Thereof	USA	6,184,210 09/270,736	2/6/2001 3/16/1999	Granted.
1735.0280003	Dipeptide Apoptosis Inhibitors and the Use Thereof	USA	6,596,693 09/653,279	7/22/2003 8/31/2000	Granted.
1735.0280004	Dipeptide Apoptosis Inhibitors and the Use Thereof	USA	6,949,516 10/429,095	9/27/2005 5/5/2003	Granted.
1735.028AU01	Dipeptide Apoptosis Inhibitors and the Use Thereof	Australia	741203 97930/98	3/7/2002 10/9/1998	Granted.
1735.028CA01	Dipeptide Apoptosis Inhibitors and the Use Thereof	Canada	2,306,692 2,306,692	9/21/2010 10/9/1998	Granted.
1735.028CN01	Dipeptide Apoptosis Inhibitors and the Use Thereof	China	Z198810022.3 98810022.3	2/18/2004 10/9/1998	Granted.
1735.028EP01	Dipeptide Apoptosis Inhibitors and the Use Thereof	EPC	98952166.1	10/9/1998	Pending.
1735.028JP01	Dipeptide Apoptosis Inhibitors and the Use Thereof	Japan	4439111 2000-515426	1/15/2010 10/9/1998	Granted.
1735.028KR01	Dipeptide Apoptosis Inhibitors and the Use Thereof	South Korea	10-0580333 10-2000-7003882	5/9/2006 10/9/1998	Granted.
1735.0290002	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	USA	6,342,611 09/168,888	1/29/2002 10/9/1998	Granted.

1735.0290004	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	USA	6,335,429 09/521,650	1/1/2002 3/8/2000	Granted.
1735.0290005	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	USA	6,759,207 09/947,387	7/6/2004 9/7/2001	Granted.
1735.0290006	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	USA	7,270,801 10/829,381	9/18/2007 4/22/2004	Granted.
1735.0320003	Gambrgic Acid, Analogs and Derivatives as Activators of Caspases and Inducers of Apoptosis	USA	6,462,041 09/495,120	10/8/2002 2/1/2000	Granted.
1735.0320005	Gambrgic Acid, Analogs and Derivatives as Activators of Caspases and Inducers of Apoptosis	USA	6,613,762 10/066,805	9/2/2003 2/6/2002	Granted.
1735.0330002	Substituted 2-Aminobenzamide Caspase Inhibitors and the Use Thereof	USA	6,620,782 09/527,225	9/16/2003 3/16/2000	Granted.
1735.0350002	Caspase Inhibitors and the Use Thereof	USA	6,355,618 09/545,565	3/12/2002 4/7/2000	Granted.
1735.0350003	Caspase Inhibitors and the Use Thereof	USA	6,716,818 09/987,417	4/6/2004 11/14/2001	Granted.
1735.0400002	Substituted Alpha-Hydroxy Acid Caspase Inhibitors and the Use Thereof	USA	6,495,522 09/649,810	12/17/2002 8/28/2000	Granted.
1735.0410002	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,906,203 09/705,840	6/14/2005 11/6/2000	Granted.
1735.0410003	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,507,762 11/072,499	3/24/2009 3/7/2005	Granted.
1735.041AU02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Australia	12/31/4040 14619/01	10/6/2005 11/3/2000	Granted.
1735.041CA02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Canada	1/16/8444 1/16/8444	3/29/2011 11/3/2000	Granted.
1735.041DE02	Substituted 4H-Chromene and Analogs as Activators of	Germany	1230232	2/25/2004	Granted.

	Caspases and Inducers of Apoptosis and the Use Thereof		976912.6	11/3/2000	
1735.041ES02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Spain	4/3/5268 9/9/4574	2/25/2004 11/3/2000	Granted.
1735.041FR02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	France	1230232 976912.6	2/25/2004 11/3/2000	Granted.
1735.041GB02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Great Britain	1230232 976912.6	2/25/2004 11/3/2000	Granted.
1735.041IT02	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Italy	1230232 976912.6	2/25/2004 11/3/2000	Granted.
1735.0420002	1735.0420002 Caspase Inhibitors for the Treatment and Prevent Chemotherapy and Radiation Therapy Induced Cell Death	USA	6,566,338 09/685,689	5/20/2003 10/11/2000	Granted.
1735.0440001	Substituted Nicotinamide and Analogs as Activators of Caspases and Apoptosis and the Use Thereof	USA	6,794,397 09/769,420	9/21/2004 1/26/2001	Granted.
1735.0450001	Substituted 1,4-Thiazepene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,861,419 09/836,548	3/1/2005 4/18/2001	Granted.
1735.0470001	Method of Identifying Immunosuppressive Agents	USA	6,828,091 09/920,332	12/7/2004 8/2/2001	Granted.
1735.0500002	Substituted Indole-2-carboxylic Acid Benzylidenehydrazide and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,747,052 10/298,946	6/8/2004 11/19/2002	Granted.
1735.0520001	Substituted 2-Aryl-4-arylamino-pyrimidine and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,716,851 10/012,444	4/6/2004 12/12/2001	Granted.
1735.0520002	Substituted 2-Aryl-4-arylamino-pyrimidine and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,226,927 10/704,448	6/5/2007 11/10/2003	Granted.
1735.0540001	Multifloro-substituted Chalcones and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,256,219 10/471,720	8/14/2007 10/16/2003	Granted.
1735.0560001	Substituted N'-(Aryl-carbonyl)-benzylidrazides, N'-Benzylidenehydrazides and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,716,859 10/141,769	4/6/2004 5/10/2002	Granted.

1735.0560002	Substituted N'-(Arylcarbonyl)-benzhydrazides, N'-Benzylidenehydrazides and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,074,813 10/816,893	7/11/2006 4/5/2004	Granted.
1735.0600001	4-Substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,794,400 10/158,827	9/21/2004 6/3/2002	Granted.
1735.0630001	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	10/146,138	7,053,117 5/30/2006 5/16/2002	Granted.
1735.063AU11	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Australia	2009200374	5/16/2002	Pending.
1735.063CA01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Canada	2,447,010	05/16/2002	Pending. Allowed. Final fees to be paid by 05/22/2011.
1735.063CN01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	China	2812067.1 3/5/9599	12/2/2009 5/16/2002	Granted.
1735.063DE01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Germany	1392683 7/12/9406	12/2/2009 5/16/2002	Granted.
1735.063EP01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	EPC	1392683 7/12/9406	12/2/2009 5/16/2002	Granted.
1735.063ES01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Spain	1392683 2741704.7	12/2/2009 5/16/2002	Granted.
1735.063FR01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	France	1392683 2741704.7	12/2/2009 5/16/2002	Granted.
1735.063GB01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	United Kingdom	1392683 2741704.7	12/2/2009 5/16/2002	Granted.
1735.063IT01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Italy	1/12/5713 7/12/9406	12/2/2009 5/16/2002	Granted.
1735.063JP01	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	Japan	4593880 2002-589478	9/24/2010 5/16/2002	Granted.
1735.0640001	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,041,685 10/164,705	5/9/2006 6/10/2002	Granted.

1735.0640002	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,435,750	11/074,077	10/14/2008	3/8/2005	Granted.
1735.064AU01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Australia	2002313633	2002313633	6/14/2007	6/10/2002	Granted.
1735.064CA01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Canada	2,449,544		6/10/2002		Pending.
1735.064CN01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	China	2813660.8		6/10/2002		Pending.
1735.064EP01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	EPC	2753336.3		6/10/2002		Pending.
1735.064ZA01	Substituted 3-Aryl-5-aryl-(1,2,4)-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	South Africa	2003/9309	2003/9309	2/23/2005	6/10/2002	Granted.
1735.0650001	7,8-Fused 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	6,858,607	10/146,139	2/22/2005	5/16/2002	Granted.
1735.0660001	Substituted Coumarins and Quinolines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,015,328	10/146,136	3/21/2006	5/16/2002	Granted.
1735.0660002	Substituted Coumarins and Quinolines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,235,674	10/989,057	6/26/2007	11/16/2004	Granted.
1735.0750001	Substituted 4H-Chromenes, 2H-Chromenes, Chromans and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,476,741	10/514,426	1/13/2009	11/16/2004	Granted.
1735.0770001	Substituted 4-Aryl-4H-pyrrolo[2,3-h]chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,528,164	10/514,427	05105/2009	11/16/2004	Granted.
1735.0780002	Derivatives of Gambogic Acid and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	7,176,234	10/609,670	2/13/2007	7/0112003	Granted.
1735.078AU02	Derivatives of Gambogic Acid and Analogs as	Australia	2003267977		09102/2010		Granted.

	Activators of Caspases and Inducers of Apoptosis		2003267977		710112003	
1735.078CNO2	Derivatives of Gambogic Acid and Analogs as Activators of Caspases and Inducers of Apoptosis	China	3815628.8 3815628.8	09108/2010	710112003	Granted.
1735.0810001	Substituted 1-Benzoyl-3-cyano-pyrrolol 1,2-a Iquinolines and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	7,135,480 101,733,229	11/14/2006	12/12/2003	Granted.
1735.0820001	3,5-Disubstituted-1,2,4-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,144,876 101,737,865	12105/2006	12/18/2003	Granted.
1735.0820002	3,5-Disubstituted-1,2,4-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,317,029 111,593,030	01108/2008	11106/2006	Granted.
1735.082AUOI	3,5-Disubstituted-1,2,4-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Australia	2003303373 2003303373	5/27/2010	12/18/2003	Granted.
1735.082CNOI	3,5-Disubstituted-1,2,4-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	China	2,0038E+11 2,0038E+11	1/30/2008	12/18/2003	Granted.
1735.082EPOI	3,5-Disubstituted-1,2,4-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	EPC	3808469.5	12118/2003		Pending. Renewal fee not paid for 12/3112010; deadline 06/30/2011.
1735.0840002	Methods of Treating Diseases Responsive to Induction of Apoptosis and Screening Assays	USA	7,592,143 10/826,909	9/22/2009	4/19/2004	Granted.
1735.088001	Protease Inhibitors for Corona virus and Sars-Co V and the Use Thereof	USA	7,504,382 10/839,753	05106/2004		3/17/2009 Granted.
1735.088CNO6	Protease Inhibitors for Corona virus and Sars-Co V and the Use Thereof	China	2,0048E+11 2,0048E+11	07102/2008	05104/2004	Granted.
1735.0940001	Derivatives of Gambogic Acid and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	7,622,497 10/580,263	11/24/2009	5/25/2006	Granted.
1735.1040001	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	USA	11,822,535	07106/2007		Pending. Allowed. Issue Fee due 05/23/2011.
1735.104AUOI	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and	Australia	2007271743	07106/2007		Pending.

	the Use Thereof					
1735.104CAO 1	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	Canada	2,656,706	07106/2007	Pending.	
1735.104CNO1	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	China	2,0078E+11	07106/2007	Pending.	
1735.104EPO1	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	EPC	7810283.7	07106/2007	Pending.	
1735.104JPO 1	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	Japan	2009-518401	07106/2007	Pending.	
1735.1050002	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	111,879,517	07118/2007	Pending.	
1735.105CA02	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Canada	2,657,931	07118/2007	Pending.	
1735.105CNO2	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	China	TBA	07118/2007	Pending.	
1735.105EP02	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	EPC	7796912.9	07118/2007	Pending.	
1735.105JPO2	3-Aryl-6-aryl-7 H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Japan	2009-520810	07118/2007	Pending.	
1735.1080001	3-aryl-6-aryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and Related Compounds as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,732,468 111,984,296	06108/2010 11/15/2007	Granted.	

Patent Status Report by Client
Client: MAXIM

EpiCept Corporation

Tuesday, April 26, 2011

MAXIM.010VES/ <i>Country:</i> <i>Attorneys:</i> <i>Title:</i>	EPC Spain MKD - Billing ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Issued 493468	90914257.2 17-Apr-96	19-Sep-90
RECEPTOR AGONISTS MAXIM.010VER/ <i>Country:</i> <i>Attorneys:</i> <i>Title:</i>	EPC France MKD - Billing ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Issued 493468	90914257.2 17-Apr-96	19-Sep-90
RECEPTOR AGONISTS MAXIM.010VGB/ <i>Country:</i> <i>Attorneys:</i> <i>Title:</i>	EPC United Kingdom MKD - Billing ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Issued 493468	90914257.2 17-Apr-96	19-Sep-90
RECEPTOR AGONISTS MAXIM.010VIV/ <i>Country:</i> <i>Attorneys:</i> <i>Title:</i>	EPC Italy MKD - Billing ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Issued 493468	90914257.2 17-Apr-96	19-Sep-90
RECEPTOR AGONISTS MAXIM.010VJP/ <i>Country:</i> <i>Attorneys:</i> <i>Title:</i>	ORD Japan amh - PS; MKD - Billing ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Issued 2845622	513349/1990 30-Oct-98	19-Sep-90
RECEPTOR AGONISTS MAXIM.010VKR/ <i>Country:</i> <i>Attorneys:</i> <i>Title:</i>	ORD Korea, Republic of amh - PS; MKD - Billing A PHARMACEUTICAL PREPARATION OR SYSTEM, AND USE THEREOF FOR INHIBITTING TUMOR GROWTH	Issued 195392	92-700628 11-Feb-99	19-Mar-92
AND THE METASTASES OF (CONTINUED) MAXIM.010VLI/ <i>Country:</i> <i>Attorneys:</i> <i>Title:</i>	EPC Liechtenstein MKD - Billing ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Issued 493468	90914257.2 17-Apr-96	19-Sep-90
RECEPTOR AGONISTS MAXIM.010VLU/ <i>Country:</i> <i>Attorneys:</i> <i>Title:</i>	EPC Luxembourg MKD - Billing ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Issued 493468	90914257.2 17-Apr-96	19-Sep-90
RECEPTOR AGONISTS MAXIM.010VNL/ <i>Country:</i> <i>Attorneys:</i> <i>Title:</i>	EPC Netherlands MKD - Billing ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Issued 493468	90914257.2 17-Apr-96	19-Sep-90
RECEPTOR AGONISTS MAXIM.010VSE/ <i>Country:</i>	EPC Sweden	Issued 493468	90914257.2 17-Apr-96	19-Sep-90

<i>Title:</i>	TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLIT	11.5 M/Fee Gra			8-Oct-14		
<i>MAXIM.066DVU/</i>							
<i>Country:</i>	United States of America	Issued	09/833896		18-Jun-02	11.5 M/Fee Due	12-Apr-01 L/C re 11.5 M/Fee Due
<i>Attorneys:</i>	CTS - Working; MKD - Billing	6407133			18-Jun-14		18-Dec-13
<i>Title:</i>	TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLITE- MEDIATED CELLULAR DAMAGE	11.5 M/Fee Gra					
<i>MAXIM.066DV2/</i>							
<i>Country:</i>	United States of America	Issued	10/171018		11-Jun-02	FU L/C re 7.5 M/Fee Due	4-Sep-11
<i>Attorneys:</i>	CTS - Working; MKD - Billing	7.5 M/Fee Grace	6730692		4-May-04	Tax 7.5	4-Nov-11
<i>Title:</i>	TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLIT	11.5 M/Fee Gra			4-May-15		
<i>FU L/C re 11.5 M/Fee Due</i>					4-Sep-15		
<i>Tax 11.5</i>					4-Nov-15		
<i>11.5 M/Fee Grace Period</i>					4-May-16		
<i>MAXIM.067A/</i>							
<i>Country:</i>	United States of America	Issued	09/467652		11-Jun-02	11.5 M/Fee Due	20-Dec-99 L/C re 11.5 M/Fee Due
<i>Attorneys:</i>	CTS - Working; MKD - Billing	6403806			11-Jun-14		11-Dec-13
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Gra					11-Jun-13
<i>MAXIM.067CV/</i>							
<i>Country:</i>	United States of America	Issued	09/974469		9-Oct-01	L/C re 11.5 M/Fee Due	4-Mar-14
<i>Attorneys:</i>	CTS - Working; MKD - Billing	6528654			4-Mar-03	Tax 11.5	4-Sep-14
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Gra			4-Mar-15		
<i>MAXIM.067C2/</i>							
<i>Country:</i>	United States of America	Issued	10/364810		10-Feb-03	L/C re 11.5 M/Fee Due	16-Sep-14
<i>Attorneys:</i>	CTS - Working; MKD - Billing	6620942			16-Mar-15		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Gra			16-Sep-15		
<i>MAXIM.067VAT/</i>							
<i>Country:</i>	Austria	Issued	1140857		99968148.9		20-Dec-99
<i>Attorneys:</i>	amh - IPS; CTS - Working; MKD - Billing				2-Jul-08		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Gra					
<i>MAXIM.067VAV/</i>							
<i>Country:</i>	Australia	Issued	24825/00		6-Nov-03		20-Dec-99
<i>Attorneys:</i>	amh - IPS; CTS - Working; MKD - Billing	763523					
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Gra					
<i>MAXIM.067VBE/</i>							
<i>Country:</i>	Belgium	Issued	1140857		99968148.9		20-Dec-99
<i>Attorneys:</i>	amh - IPS; CTS - Working; MKD - Billing				2-Jul-08		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Due					
<i>MAXIM.067VCA/</i>							
<i>Country:</i>	Canada	Issued	2356871		2356871		20-Dec-99
<i>Attorneys:</i>	amh - IPS; CTS - Working; MKD - Billing				14-Sep-10		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Due					
<i>MAXIM.067VCH/</i>							
<i>Country:</i>	Switzerland	Issued	1140857		99968148.9		20-Dec-99
<i>Attorneys:</i>	amh - IPS; CTS - Working; MKD - Billing				2-Jul-08		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	11.5 M/Fee Due					
<i>MAXIM.067VCN/</i>							
<i>Country:</i>	China (People's Republic)	Issued	ZL99814906.3		99814906.3		20-Dec-99
<i>Attorneys:</i>	amh - IPS; CTS - Working; MKD - Billing				30-Jun-04		

<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VCY/</i>	EPC	Issued		99968148.9	20-Dec-99
<i>Country:</i>	Cyprus, Republic of	1140857		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VDE/</i>	EPC	Issued		99968148.9	20-Dec-99
<i>Country:</i>	Germany	69939027.3-08		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VDK/</i>	EPC	Issued		99968148.9	20-Dec-99
<i>Country:</i>	Denmark	1140857		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VEP/</i>	ORD	Issued		99968148.9	20-Dec-99
<i>Country:</i>	European Patent Convention	1140857		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VES/</i>	EPC	Issued		99968148.9	20-Dec-99
<i>Country:</i>	Spain	1140857		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VEV/</i>	EPC	Issued		99968148.9	20-Dec-99
<i>Country:</i>	Finland	1140857		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VER/</i>	EPC	Issued		99968148.9	20-Dec-99
<i>Country:</i>	France	1140857		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VGB/</i>	EPC	Issued		99968148.9	20-Dec-99
<i>Country:</i>	United Kingdom	1140857		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VGR/</i>	EPC	Issued		99968148.9	20-Dec-99
<i>Country:</i>	Greece	1140857		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VHK/</i>	ORD	Issued		2102715.8	20-Dec-99
<i>Country:</i>	Hong Kong	HK1040998		24-Apr-09	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VIE/</i>	EPC	Issued		99968148.9	20-Dec-99
<i>Country:</i>	Ireland	1140857		2-Jul-08	
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing				
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				
<i>MAXIM.067VII/</i>	ORD	Issued		143570	20-Dec-99
<i>Country:</i>	Israel	143570		21-Nov-06	

<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing						
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	INDIA	Issued	IN/PCT/2001/00601				20-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		205849		13-Apr-07		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	INDIA	Issued					
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		1140857		99968148.9		20-Dec-99
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				2-Jul-08		
<i>Country:</i>	ITALY	Issued					
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		4139082		2000-591009		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE				13-Jun-08		
<i>Country:</i>	JAPAN	Issued					20-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing						
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	KOREA, REPUBLIC OF	Pending	10-2001-7007847				20-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing						
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	LUXEMBOURG	Issued			99968148.9		20-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		1140857		2-Jul-08		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	MONACO	Issued			99968148.9		20-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		1140857		2-Jul-08		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	NETHERLANDS	Issued			99968148.9		20-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		1140857		2-Jul-08		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	NEW ZEALAND	Issued			512935		20-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		512935		8-Dec-03		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	PORTUGAL	Issued			99968148.9		20-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		1140857		2-Jul-08		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	SWEDEN	Issued			99968148.9		20-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		1140857		2-Jul-08		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>	TAIWAN	Issued			88122820		23-Dec-99
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		1243166		11-Nov-05		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE						
<i>Country:</i>		Issued			2001/4552		20-Dec-99

<i>Country:</i>	South Africa	2001/4552	27-Mar-02
<i>Attorneys:</i>	anh - IPS; CTS - Working; MKD - Billing		
<i>Title:</i>	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE		
<i>Country:</i>	United States of America	Issued	
<i>Attorneys:</i>	MKD - Billing	09/27/801	
<i>Title:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE	62/0781	7-Aug-01 Tax 11.5
<i>Country:</i>	United States of America	11 1/2 YR M/FE	7-Aug-13
<i>Attorneys:</i>	MKD - Billing		
<i>Title:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE		
<i>Country:</i>	DIY	Issued	
<i>Attorneys:</i>	United States of America	09/765929	
<i>Title:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE	6350785	26-Feb-02 Tax 11.5
<i>Country:</i>	United States of America	11 1/2 YR M/FE	26-Feb-14
<i>Attorneys:</i>	MKD - Billing		
<i>Title:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE		
<i>Country:</i>	ORZ	Issued	
<i>Attorneys:</i>	New Zealand	513272	513272
<i>Title:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE		
<i>Country:</i>	anh - IPS; MKD - Billing		
<i>Attorneys:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE		
<i>Title:</i>	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE		
<i>Country:</i>	ORZ	Issued	
<i>Attorneys:</i>	Australia	779215	200061044
<i>Title:</i>	USE OF DIPHENYLIODONODIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC		14-Jan-00
<i>Country:</i>	United States of America	10/160745	
<i>Attorneys:</i>	MKD - Billing	6790440	14-Sep-04 FU LC re 7.5 M/fee Due
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/fee Grace		14-Mar-12
<i>Country:</i>	DIY	Issued	
<i>Attorneys:</i>	United States of America	14-Sep-15	30-May-02 LC re 7.5 M/fee Due
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/fee Grace		14-Jan-12
<i>Country:</i>	United States of America	14-Jan-16	
<i>Attorneys:</i>	MKD - Billing	14-Mar-16	
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/fee Grace		
<i>Country:</i>	DIY	Issued	
<i>Attorneys:</i>	United States of America	14-Sep-16	17-May-13
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/fee Grace		
<i>Country:</i>	United States of America	10/160360	30-May-02 LC re 7.5 M/fee Due
<i>Attorneys:</i>	MKD - Billing	6893633	17-Sep-12
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/fee Grace		
<i>Country:</i>	DIY	Issued	
<i>Attorneys:</i>	United States of America	10/160368	17-May-11
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/fee Grace		
<i>Country:</i>	United States of America	6821510	23-Nov-04 FU LC re 7.5 M/fee Due
<i>Attorneys:</i>	MKD - Billing	Tax 7.5	23-Mar-12
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/fee Grace		
<i>Country:</i>	United States of America	23-Nov-15	23-Nov-11
<i>Attorneys:</i>	MKD - Billing	23-Mar-16	
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/fee Grace		
<i>Country:</i>	United States of America	23-May-16	
<i>Attorneys:</i>	MKD - Billing	23-Nov-16	
<i>Title:</i>	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATION 7.5 M/fee Grace		
<i>Country:</i>	ORZ	Published	
<i>Attorneys:</i>	PCT/US2010/030604	9-Apr-10 File Refs in All IL Application	18-May-11

<i>Country:</i>	Patent Cooperation Treaty	IDS in US Appli	18-May-11
<i>Attorneys:</i>	anh - IPS; MKD - Billing; MZP - Working	File Keep w/Den	18-May-11
<i>Title:</i>	COMPOSITION AND USE OF N-ALPHA-METHYLHISTAMINE DIHYDR I/C 30 Month N	16-Jul-11	
	FU I/C re 30 Month NP / IPS	16-Aug-11	
		16-Sep-11	
	Prepare FENP Memo / Asst	18-Sep-11	
	NP w/out Late Fee / ATTY	2-Oct-11	
	NP w/\$300 Late Fee / ATTY	9-Oct-11	
	File Nat'l Phase in US? / ATTY	16-Oct-11	
	NP 30 Month Date FINAL / IPS	16-Oct-11	
	NP 31 Month Date FINAL / IPS	16-Nov-11	
<i>Country:</i>	FW	Issued	08/932406
<i>Attorneys:</i>	United States of America	6063373	16-May-00 Tax 11.5
<i>Title:</i>	MKD - Billing	11.5 GRACE PE	16-May-12
	ENHANCED ACTIVATION OF NK CELLS USING AN NK CELL ACTIVATOR AND A HYDROGEN PEROXIDE		
		Issued	09/516738
<i>Country:</i>	CON	6245563	12-Jun-01 Tax 11.5
<i>Attorneys:</i>	United States of America	11 I/2 YR M/FE	12-Jun-13
<i>Title:</i>	MKD - Billing		
	ENHANCED ACTIVATION OF NATURAL KILLER CELLS USING AN NK CELL ACTIVATOR AND A		
	HYDROGEN PEROXIDE SCAVENGER OR INHIBITOR		
		Issued	09/033110
<i>Country:</i>	CON	6003516	21-Dec-99 Tax 11.5
<i>Attorneys:</i>	United States of America		
<i>Title:</i>	MKD - Billing		
	METHOD FOR TREATMENT OF CANCER AND INFECTIOUS DISEASE		
		Issued	08/969384
<i>Country:</i>	CIP	6071942	6-Jun-00 Tax 11.5
<i>Attorneys:</i>	United States of America		
<i>Title:</i>	MKD - Billing	11.5 GRACE PE	6-Jun-12
	ELEVATION OF CIRCULATING BLOOD HISTAMINE LEVELS		
		Issued	13-Nov-97 11 I/2 YR I/C
		2-Mar-98 Tax 11.5	21-Jun-11
		17-Sep-97 11 I/2 YR I/C	16-May-11
		16-Nov-11	
		12-Dec-12	12-Jun-12
		13-Nov-97 11 I/2 YR I/C	6-Dec-11
		21-Jun-11	6-Jun-11

Docket No. CAM/No. _____ Client Owner _____ Patent Title _____ Inventors _____ App# _____ Pat # _____
 County Status _____

010071-0005-007 EPICEPT CORPORATION
 INTRADERMAL PENETRATION AGENTS FOR WILFRIED FISCHER KATHARINASTOEGER 2001245449 2001245449
 TOPICAL LOCAL ANESTHETICS PETRA FUBBER
 USING PATCH A

301717-007004 EPICEPT, INC.
 Australia Registered
 6-Mar-01 5-Jul-07

Attorneys: ILENE B. TANNEN PETER G. THURLOW

010071-0005-008 EPICEPT CORPORATION
 INTRADERMAL PENETRATION AGENTS FOR WILFRIED FISCHER KATHARINASTOEGER 521470 521470
 TOPICAL LOCAL ANESTHETICS PETRA FUBBER
 USING PATCH A

301717-008004 EPICEPT, INC.
 New Zealand Registered
 March 6, 2001 11-Nov-04

Attorneys: ILENE B. TANNEN PETER G. THURLOW

010071-0005-009 EPICEPT CORPORATION
 INTRADERMAL PENETRATION AGENTS FOR WILFRIED FISCHER KATHARINASTOEGER 20027008828 237220
 TOPICAL LOCAL ANESTHETICS PETRA FUBBER
 USING PATCH A

301717-009004 EPICEPT, INC.
 Mexico Registered
 6-Mar-01 26-May-06

Attorneys: ILENE B. TANNEN PETER G. THURLOW

010071-0005-012

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOEGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

13-566701

209506

301717-012004

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOEGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

6-Mar-01

Japan
Pending

Attorneys:

ILENE B. TANNEN PETER G. THURLLOW

010071-0005-056

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOEGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

2002/01/6/40

209506

301717-056004

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOEGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

6-Mar-01

India
Registered

Attorneys:

ILENE B. TANNEN PETER G. THURLLOW

010071-0005-117

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOEGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

1-2001-00573

301717-117004

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOEGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

8-Mar-01

Philippines
Filed Wait Exam

Attorneys:

ILENE B. TANNEN PETER G. THURLLOW

010071-0005-149

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOEGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

PV2002-3030

301717-149004
Czech Republic
Pending

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0005-158

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

301717-158004

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

Israel

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0005-187

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

301717-187004

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

Republic of Korea

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0005-228

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

301717-228004

INTRADERMAL
PENETRATION
AGENTS FOR WILFRIED FISCHER
TOPICAL KATHARINASTOGER
LOCAL PETRA FIBBER
ANESTHETICS
USING A
PATCH

Patent Cooperation Treaty

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

Completed

010071-0005-999 EPICEPT CORPORATION 6,455,066

INTRADERMAL PENETRATION AGENTS FOR TOPICAL LOCAL ANESTHETICA ADMINISTRATION
WILFRIED FISCHER
KATHARINASTOEGER
PETRA FIBBER

301717-999004 EPICEPT CORPORATION 10-Mar-00 24-Sep-02

United States of America Registered

Attorney's

ILENE B. TANNEN PETER G. THURLLOW

010071-0010-012 EPICEPT CORPORATION 2002-504977

METHODS AND COMPOSITION S FOR TREATING PAIN OF THE MUCOUS MEMBRANE
ROBERT O. WILLIAMS
FENGZHANG

301717-012009 EPICEPT CORPORATION 26-Jun-01

Japan Pending

Attorney's

ILENE B. TANNEN PETER G. THURLLOW

010071-0010-158 EPICEPT CORPORATION 153656

METHODS AND COMPOSITION S FOR TREATING PAIN OF THE MUCOUS MEMBRANE
ROBERT O. WILLIAMS
FENGZHANG

301717-158009 EPICEPT CORPORATION
Israel Filed Wait Exam
JOHN J. KOLENG GAVRIL
W. PASTERNAK YURI A.
KOLESNIKOV

Attorney's

ILENE B. TANNEN PETER G. THURLLOW

010071-0010-227 EPICEPT CORPORATION 1948733.9 1296650

METHODS AND COMPOSITION S FOR TREATING PAIN OF THE MUCOUS MEMBRANE
ROBERT O. WILLIAMS
FENGZHANG

301717-227009 EPICEPT CORPORATION 26-Jun-01 2-Mar-05

European Patent Office EPP Granted

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0010-228 EPICEPT CORPORATION

METHODS AND
COMPOSITION
S FOR
TREATING
PAIN OF THE
MUCOUSMEMB
RANE
ROBERT O. WILLIAMS
FENGZHANG
PCTUSOIP20922

301717-228009 EPICEPT CORPORATION

JOHN J. KOLENG GAVRIJL
W. PASTERNAK YURI A.
KOLESNIKOV
26-Jun-01

Patent Cooperation Treaty
Completed

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-001 EPICEPT CORPORATION

TOPICAL
COMPOSITION
S AND
METHODS FOR
TREATING
PAIN
ROBERT O. WILLIAMS
FENGZHANG
2,457,780
2,457,780

301717-001015 EPICEPT CORPORATION

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-007 EPICEPT CORPORATION

TOPICAL
COMPOSITION
S AND
METHODS FOR
TREATING
PAIN
ROBERT O. WILLIAMS
FENGZHANG
2002335635
2002335635

301717-007015 EPICEPT CORPORATION

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-008 EPICEPT CORPORATION

TOPICAL
COMPOSITION
S AND
METHODS FOR
TREATING
PAIN
ROBERT O. WILLIAMS
FENGZHANG
531547
531547

301717-008015 EPICEPT CORPORATION

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

New Zealand
Registered

14-Aug-02 December 14,2006

010071-0016-009 EPICEPT CORPORATION
301717-009015 EPICEPT CORPORATION

TOPICAL COMP ROBERT O. WILLIAMS FENIP A/12004/001368
14-Aug-02 February 29, 2008

255023

Mexico
Registered

Attorneys:

ILENE B. TANNEN THOMAS E. FRIEBEL PETER G. THURLOW

010071-0016-010 EPICEPT CORPORATION TOPICAL COMP ROBERT O. WILLIAMS FEN1813-2002 12-Aug-02 45.5
301717-010015 EPICEPT CORPORATION 8-Jul-09

Chile
Registered

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-023 EPICEPT CORPORATION TOPICAL COMP ROBERT O. WILLIAMS FEN 6109763 HK1089364 5-Feb-10
301717-023015 EPICEPT CORPORATION 14-Aug-02

Hong Kong
Registered

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-025 EPICEPT CORPORATION TOPICAL COMPOSITION ROBERT O. WILLIAMS 2002-001562
METHODS FOR FENGZHANG TREATING PAIN

301717-025015 EPICEPT CORPORATION 15-Aug-02

Venezuela
Pending

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-036 EPICEPT CORPORATION TOPICAL COMPOSITION ROBERT O. WILLIAMS P020103069
METHODS FOR FENGZHANG TREATING PAIN

301717-036015 EPICEPT CORPORATION 14-Aug-02

Argentina
Pending

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-146 EPICEPT CORPORATION TOPICAL COMPOSITION ROBERT O. WILLIAMS 2820112.4 ZL02820112.4
METHODS FOR FENGZHANG TREATING PAIN

301717-146015 EPICEPT CORPORATION 14-Aug-02 10-Jun-09

China
Registered

Attorneys:

ILENE B. TANNEN PETER G. THURLOW

010071-0016-158 EPICPT CORPORATION 160388
 301717-158015 EPICPT CORPORATION 160388
 Israel May 18, 2010
 Registered Attorneys: ILENE B. TANNEN PETER G. THURLLOW

010071-0016-227 EPICPT CORPORATION 2770398.2
 EPICPT CORPORATION ROBERT O. WILLIAMS
 METHODS FOR FENGZHANG
 TREATING
 PAIN

301717-227015 EPICPT CORPORATION 14-Aug-02
 European Patent Office
 Pending Attorneys: ILENE B. TANNEN PETER G. THURLLOW

010071-0016-228 EPICPT CORPORATION PCT:US 02 / 2587 1
 EPICPT CORPORATION ROBERT O. WILLIAMS
 S AND
 METHODS FOR FENGZHANG
 TREATING
 PAIN

301717-228015 EPICPT CORPORATION 14-Aug-02
 Patent Cooperation Treaty
 Completed Attorneys: ILENE B. TANNEN PETER G. THURLLOW CELEMORRIS

010071-0016-999 EPICPT CORPORATION 91,931,293 6,638,981
 EPICPT CORPORATION ROBERT O. WILLIAMS
 S AND
 METHODS FOR FENGZHANG
 TREATING
 PAIN

301717-999015 EPICPT CORPORATION 17-Aug-01 28-Oct-03
 United States of America
 Registered Attorneys: ILENE B. TANNEN PETER G. THURLLOW

010071-0018-228 EPICPT CORPORATION PCT:US 02 / 33195
 EPICPT CORPORATION PAUL MASON
 STERILE
 BREATHABLE
 PATCH FOR
 TREATING
 WOUND PAIN

301717-228017 EPICPT CORPORATION 17-Oct-02
 Patent Cooperation Treaty
 Completed Attorneys: ILENE B. TANNEN PETER G. THURLLOW CELEMORRIS

010071-0026-999 EPICEPT CORPORATION 101.172.455 6-509-028

301717-999025 United States of America Registered 17-Jun-02 21-Jan-03

Attorneys:

ILENE B. TANNEN ILENE B. TANNEN

010071-0027-999 EPICEPT CORPORATION 6,746,689

301717-999026 United States of America Registered 10-Mar-00 8-Jun-04

Attorneys:

ILENE B. TANNEN PETER G. THURLLOW

010071-0028-999 EPICEPT CORPORATION 5,817,699

301717-999027 United States of America Registered 6-Oct-98

Attorneys:

ILENE B. TANNEN PETER G. THURLLOW

010071-0048-012 EPICEPT CORPORATION 2008-163375

METHODS AND COMPOSITIONS FOR TREATING PAIN OF THE MUCOUS MEMBRANE

ROBERT O. WILLIAMS FENGZHANG

301717-012050 EPICEPT CORPORATION 23-Jun-08

JOHN I. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV

Attorneys:

ILENE B. TANNEN PETER G. THURLLOW

Japan Pending

010071-0048-023

EPICEPT CORPORATION

METHODS AND
COMPOSITION
S FOR
TREATING
PAIN OF THE
MUCOUS
MEMBRANE

51108834

301717-023050

EPICEPT CORPORATION

JOHN I. KOLENG GAVRIL
W. PASTERNAK YURI A.
KOLESNIKOV

28-Feb-05

Hong Kong
Filed Wait Exam

Attorneys:

ILENE B. TANNEN PETER G. THURLLOW

010071-0051-999

EPICEPT CORPORATION

KETAMINE
AND N-B U TYI
P-AMINOBEZO
ATE (sic) IN
PLIO

09:350,062

6.017.961

United States of America
Registered

EPICEPT CORPORATION

Attorneys:

ILENE B. TANNEN PETER G. THURLLOW

8-Jul-99

25-Jan-00

010071-0053-009

EPICEPT CORPORATION

TOPICAL
COMPOSITION
S AND
METHODS FOR
TREATING
PAIN

Pat. 6,720,077/013047

301717-009054

EPICEPT CORPORATION

October 19, 2007

Mexico
Pending

Attorneys:

ILENE B. TANNEN PETER G. THURLLOW

EXHIBIT C

Trademarks

[See Attached]

MAXIM PHARMACEUTICALS, INC. / EPICEPT CORPORATION
 TRADEMARK STATUS REPORTS

Updated: April 26, 2011

MAXIM PHARMACEUTICALS, INC. - U.S. TRADEMARK APPLICATION/REGISTRATIONS:

MARK	KN/OB REF. NO. (MAXIM)	CLASS: GOODS/SERVICES	APP. NO./ APP. DATE	REG. NO./ REG. DATE	STATUS/ COMMENTS
CEPLENE	157T	5: Pharmaceuticals, namely, compositions for the treatment of cancer	76/138212 9/29/2000	2967403 7/12/2005	REGISTERED Renewal due 07/11/2115

	Ceplene		221T	5: Pharmaceuticals, namely, compositions for the treatment of cancer	85/021009	4/22/2010		PENDING
								NOA issued 11/16/10 SOU/1 st due 5/15/11
	VONTIV		156T	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	76/138211	9/29/2000	3252103	REGISTERED
								Section 8 & 15 due 06/12/11 Renewal due 06/12/11

MAXIM PHARMACEUTICALS, INC. - FOREIGN TRADEMARK REGISTRATIONS

MARK	COUNTRY	KMOB REF. NO. (MAXIM)	CLASS: GOODS/SERVICES	APP. NO./ APP. DATE	REG. NO./ REG. DATE	STATUS/ COMMENTS
CEPLENE	Australia	157W/AU	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	858297	858297	REGISTERED
						Renewal due 11/23/20
CEPLENE	Canada	157W/CA	5: Pharmaceuticals, namely, compositions for the treatment of cancer	107834	TMA687350	REGISTERED
						Renewal due 05/09/22
CEPLENE	China	157W/CN	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	2001045526	1760656	REGISTERED
						Renewal due 05/07/12
CEPLENE	European Community	157W/EU	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	1965656	1965656	REGISTERED
						Renewal due 11/22/20
CEPLENE	Iceland	157W/IS	5: Pharmaceuticals	2516/2003	30/2004	REGISTERED
						Renewal due 01/102/14

CEPLENE	Israel	157WLI	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	144206	144206	REGISTER ED
CEPLENE	Japan	157WJP	5: Composed pharmaceuticals for treatment of cancer; Composed pharmaceuticals for treatment of infectious disease; other pharmaceuticals	2001-029763	4671668	RENEWAL due 11/26/21
CEPLENE	Liechtenstein	157WLI	5: Pharmaceuticals	13015	13015	RENEWAL due 11/26/21
CEPLENE	New Zealand	157WNZ	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	627694	627694	RENEWAL due 09/29/17
CEPLENE	Norway	157WNO	5: Pharmaceutical preparations	200309400	224104	RENEWAL due 09/01/14
CEPLENE	Switzerland	157WCH	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	13973 / 2000	483420	RENEWAL due 11/23/20
VONTIV	Australia	156WAU	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	858080	858080	RENEWAL due 11/27/20
VONTIV	Canada	156WCA	5: Pharmaceuticals, namely compositions for the treatment of cancer and viral hepatitis	1078345	TMA727471	RENEWAL due 10/30/23

VONTIV	China	156WCN	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	2001045525	1760655	REGISTERED
VONTIV	European Community	156WEU	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	3/28/2001	5/7/2002	Renewal due 05/07/12
VONTIV	Japan	156WJP	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	11122/00	5/23/2002	Renewal due 11/22/20
VONTIV	Switzerland	156WCH	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	2001-027100	4503151	REGISTERED
				03/26/01	08/31/01	Renewal due 08/31/11
				11123/00	4/4/2001	Renewal due 11/23/20

EPICEPT CORPORATION - U.S. TRADEMARK APPLICATIONS

MARK	KMOB REF. NO. (EPCPT®)	CLASS: GOODS SERVICES	APP. NO./ APP. DATE	REG. NO./ REG. DATE	STATUS / COMMENTS
AMIKET	001T	5: Topical analgesics			UNFILED
CROLIBULIN	MAXIM.20T	5: Pharmaceutical preparation for the treatment of cancer	85/009435 4/8/2010		PENDING - TO BE ABANDONED NOA issued 10/26/10

DISCLAIMER

To the best of our knowledge, the information contained in this Status Report is accurate. This Status Report is not to be used or relied upon for any purpose other than your general information. The Status Report contains confidential material and is protected by the attorney-client privilege.
111282541/PJP/0428 11

TRADEMARK REPORT
EPICEPT CORPORATION
Jones Day
April 26, 2011

LIDOPAIN	App.No.	Reg. No.	Docket No. 010071-0046-007	Australia
	App. Date	Reg. Date	Cam No. 301717-007014	

EPICEPT CORPORATION	1039048	1039048		Registered
	25-Jan-05	25-Jan-05	Renewal Due January 25, 2015	

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

LIDOPAIN	App.No.	Reg. No.	Docket No. 010071-0046-001	Canada
	App. Date	Reg. Date	Cam No. 301717-001014	

EPICEPT CORPORATION	1,244,794 TMA725,845			Registered
	25-Jan-05	10-Oct-08	Renewal Due October 10, 2023	

ADHESIVE PATCH IMPREGNATED WITH TOPICAL ANALGESIC

ceplene.cn	App.No.	Reg. No.	Docket No. 010071-0067-146	China
	App. Date	Reg. Date	Cam No. 301717-146011	

EPICEPT CORPORATION		December 13, 2007	Renewal Due December 13, 2012	Registered
---------------------	--	-------------------	-------------------------------	------------

ceplene.com.cn	App.No.	Reg. No.	Docket No. 010071-0068-146	China
	App. Date	Reg. Date	Cam No. 301717-146066	

EPICEPT CORPORATION		December 13, 2007	Renewal Due December 13, 2012	Registered
---------------------	--	-------------------	-------------------------------	------------

ceplene.net.cn App.No. Reg. No. Docket No. 010071-0069-146 China
App. Date Reg. Date Cam No. 301717-146069

EPICEPT CORPORATION December 13,2007 Renewal Due December 13,2012 Registered

ceplene.org.cn App.No. Reg. No. Docket No. 010071-0070-146 China
App. Date Reg. Date Cam No. 301717-146012

EPICEPT CORPORATION December 13,2007 Renewal Due December 13,2012 Registered

EPICEPT App.No. Reg. No. Docket No. 010071-0054-146 China
App. Date Reg. Date Cam No. 301717-146063

EPICEPT CORPORATION 6432338 6432338 December 12, 2007 March 28,2010 Renewal Due March 27, 2020 Registered

5 PHARMACEUTICAL PREPARATIONS, NAMELY ANTICANCER AGENTS AND TOPICAL ANALGESICS

epicept in Chinese App.No. Reg. No. Docket No. 010071-0076-146 China
App. Date Reg. Date Cam No. 301717-146076

EPICEPT CORPORATION December 13,2007 Renewal Due December 13,2012 Registered

EPICEPT IN CHINESE CHARACTERS App.No. Reg. No. Docket No. 010071-0062-146 China
App. Date Reg. Date Cam No. 301717-146064

EPICEPT CORPORATION 6432337 6432337 December 12, 2007 March 28,2010 Renewal Due March 27, 2020 Registered

5 PHARMACEUTICAL PREPARATIONS, NAMELY ANTICANCER AGENTS AND TOPICAL ANALGESICS

epicept.net.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0065-146 Cam No. 301717-146009	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
epicept.org.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0066-146 Cam No. 301717-146010	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
Internet Keyword Registration for epiceptcorporation " "	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0064-146 Cam No. 301717-146001	China
EPICEPT CORPORATION		February 21, 2008	Renewal Due February 21, 2018	Registered
Internet Keyword Registration for CEPLNE	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0078-146 Cam No. 301717-146005	China
EPICEPT CORPORATION		December 14,2007	Renewal Due December 14,2017	Registered
Internet Keyword Registration for Epicept in Chinese	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0080-146 Cam No. 301717-146007	China
EPICEPT CORPORATION		December 14,2007	Renewal Due December 14,2017	Registered
Internet Keyword Registration for LIDOPAIN	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0079-146 Cam No. 301717-146006	China

EPICEPT CORPORATION

December 12, 2007

Renewal Due December 14, 2017

Registered

Internet Keyword Registration for Lidopain in Chinese

App.No.
App. Date

Reg. No.
Reg. Date

Docket No. 010071-0081-146
Cam No. 301717-146008

China

EPICEPT CORPORATION

December 14, 2007

Renewal Due December 14, 2017

Registered

Internet Keyword Registratinn for EPICEPT

App.No.
App. Date

Reg. No.
Reg. Date

Docket No. 010071-0077-146
Cam No. 301717-146003

China

EPICEPT CORPORATION

December 14, 2007

Renewal Due December 14, 2017

Registered

LIDOPAIN

App.No.
App. Date

Reg. No.
Reg. Date

Docket No. 010071-0046-146
Cam No. 301717-146014

China

EPICEPT CORPORATION

4510075
February 21, 2005

4510075
28-Jul-08

Renewal Due July 27, 2018

Registered

5 TOPICAL PATCH FOR USE IN THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

Lidopain in Chinese

App.No.
App. Date

Reg. No.
Reg. Date

Docket No. 010071-0075-146
Cam No. 301717-146075

China

EPICEPT CORPORATION

13-Dec-07

Renewal Due December 13, 2012

Registered

LIDOP AIN IN CHINESE CHARACTERS

App.No.
App. Date

Reg. No.
Reg. Date

Docket No. 010071-0047-146
Cam No. 301717-146048

China

EPICEPT CORPORATION

4510076

4510076

Registered

February 21, 2005

7-Jul-08

Renewal Due July 6, 2018

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

lidopain.cn	App. No.	Reg. No.	Docket No. 010071-0071-146	China
	App. Date	Reg. Date	Cam No. 301717-146071	

EPICEPT CORPORATION		December 13, 2007	Renewal Due December 13, 2012	Registered
---------------------	--	-------------------	-------------------------------	------------

lidopain.com.cn	App. No.	Reg. No.	Docket No. 010071-0072-146	China
	App. Date	Reg. Date	Cam No. 301717-146072	

EPICEPT CORPORATION		December 13, 2007	Renewal Due December 13, 2012	Registered
---------------------	--	-------------------	-------------------------------	------------

lidopain.net.cn	App. No.	Reg. No.	Docket No. 010071-0073-146	China
	App. Date	Reg. Date	Cam No. 301717-146073	

EPICEPT CORPORATION		December 13, 2007	Renewal Due December 13, 2012	Registered
---------------------	--	-------------------	-------------------------------	------------

lidopain.org.cn	App. No.	Reg. No.	Docket No. 010071-0074-146	China
	App. Date	Reg. Date	Cam No. 301717-146074	

EPICEPT CORPORATION		December 13, 2007	Renewal Due December 13, 2012	Registered
---------------------	--	-------------------	-------------------------------	------------

LIDOPAIN	App. No.	Reg. No.	Docket No. 010071-0046-300	European Community
	App. Date	Reg. Date	Cam No. 301717-300014	

EPICEPT CORPORATION	4256699	4256699		Registered
	25-Jan-05	25-Jan-05		

Renewal Due January 25, 2015

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

EPICEPT (STYLIZED)	App. No.	Reg. No.	Docket No. 010071-0009-003	Germany
	App. Date	Reg. Date	Cam No. 301717-003008	

EPICEPT GMBH	39982506.1	39982506		Registered
	28-Dec-99	12-Apr-00		
			Renewal Due December 31, 2019	

5 PHARMACEUTICAL PREPARATIONS, NAMELY TOPICAL ANALGESICS

LIDOPAIN	App. No.	Reg. No.	Docket No. 010071-0046-023	Hong Kong
	App. Date	Reg. Date	Cam No. 301717-023014	

EPICEPT CORPORATION	300364653	300364653		Registered
	February 1, 2005	February 1, 2005		
			Renewal Due January 31, 2015	

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

LIDOPAIN IN CHINESE CHARACTERS	App. No.	Reg. No.	Docket No. 010071-0047-023	Hong Kong
	App. Date	Reg. Date	Cam No. 301717-023048	

EPICEPT CORPORATION	300377442	300377442		Registered
	February 28, 2005	February 28, 2005		
			Renewal Due February 27, 2015	

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

LIDOPAIN	App. No.	Reg. No.	Docket No. 010071-0046-056	India
	App. Date	Reg. Date	Cam No. 301717-056014	

EPICEPT CORPORATION 1348025 1348025 Registered
30-Mar-05 30-Mar-05
Renewal Due March 30, 2015

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

LIDOPAIN App.No. Reg. No. Docket No. 010071-0046-012 Japan
App. Date Reg. Date Cam No. 301717-012014

EPICEPT CORPORATION 2005-6730 4985525 Registered
28-Jan-05 8-Sep-06
Renewal Due September 8, 2016

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS, AND OTHER PHARMACEUTICAL PREPARATIONS

LIDOPAIN App.No. Reg. No. Docket No. 010071-0046-009 Mexico
App. Date Reg. Date Cam No. 301717-009014

EPICEPT CORPORATION 701065 876244 Registered
February 9, 2005 April 18, 2005
Renewal Due February 9, 2015

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

EPICEPT App.No. Reg. No. Docket No. 010071-0054-999 United States of America
App. Date Reg. Date Cam No. 301717-999056

EPICEPT CORPORATION 78/972,569 3,265,139 Registered
September 12, 2006 17-Jul-07
Section 8 & 15 Deadline July 17, 2013
Renewal Due July 17, 2017

5 PHARMACEUTICAL PREPARATIONS, NAMELY TOPICAL ANALGESICS

LIDOPAIN	App. No.	Reg. No.	Docket No. 010071-0015-999	United States of America
	App. Date	Reg. Date	Cam No. 301717-999014	

EPICEPT CORPORATION	74/467,358	8-Dec-93	1,906,291	Registered
			18-Jul-95	
			Renewal Due July 18,2015	

5 ADHESIVE PATCH IMPREGNATED WITH TOPICAL ANALGESIC

LIDOPAIN	App. No.	Reg. No.	Docket No. 010071-0046-999	United States of America
	App. Date	Reg. Date	Cam No. 301717-999052	

EPICEPT CORPORATION	78/567,710	15-Feb-05	3,366,649	Registered
		8-Jan-08		
			Section 8 & 15 Deadline January 8, 2014	
			Renewal Due January 8, 2018	

5 MEDICATED TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

EXHIBIT D

Mask Works

None.